Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...

A pair of rival hospitals in Indiana walked back their merger application, shortly before the state was expected to rule on ...

The company's future now appears to be in flux, as simufilam was its only drug in clinical trials, The New York Times reported. Also: a Roche lung cancer drug has failed to improve survival; pharma ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

What is the outlook of the IWM ETF? We explain why the Russell 2000 index rally has more room to go on in the near term.

H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company announced results from its ReThink-ALZ Phase 3 trial with ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Wall Street witnessed a historic day with the S&P 500 and Dow Jones Industrial Average reaching record highs. The Russell ...